AGENUS INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
AGENUS INC (AGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 89.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-16
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 89.00%, a 3.49% increase from fiscal 2024.
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 86.00%, a 19.44% increase from fiscal 2023.
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 72.00%, a 5.88% increase from fiscal 2022.
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 68.00%, a 38.78% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|
| 2025-12-31 | 89.00% 10-K · filed 2026-03-16 | |
| 2024-12-31 | 86.00% 10-K · filed 2026-03-16 | |
| 2023-12-31 | 72.00% 10-K · filed 2026-03-16 | |
| 2022-12-31 | 68.00% 10-K · filed 2025-03-17 | |
| 2021-12-31 | 49.00% 10-K · filed 2024-03-14 | |
| 2020-12-31 | 66.00% 10-K · filed 2023-03-16 | |
| 2019-12-31 | 64.00% 10-K · filed 2022-03-01 | |
| 2018-12-31 | 64.00% 10-K · filed 2021-03-16 | |
| 2017-12-31 | 65.00% 10-K · filed 2020-03-16 | |
| 2016-12-31 | 65.00% 10-K · filed 2019-03-18 | |
| 2015-12-31 | 77.00% 10-K · filed 2018-03-16 | |
| 2014-12-31 | 84.00% 10-K · filed 2017-03-16 | 84.22% 10-K · filed 2015-03-16 |
| 2013-12-31 | 87.00% 10-K · filed 2016-03-15 | 86.50% 10-K · filed 2014-03-07 |
| 2012-12-31 | 96.00% 10-K · filed 2015-03-16 | |
| 2011-12-31 | 103.00% 10-K · filed 2014-03-07 | |
| 2010-12-31 | 104.00% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |